SiNtx Technologies, Inc. - SINT STOCK NEWS

SINTX Technologies announced the first shipment of its new FleX SN-PEEK product, launched on July 20, 2021, designed for orthopedic implants. This innovative composite material combines the bioactivity of silicon nitride with the established properties of Zeniva PEEK, enhancing bone healing and infection resistance. The product aims to improve surgical outcomes across various applications, including spine surgery and joint replacements. SINTX continues to expand its customer base in the biomedical market, leveraging its expertise in manufacturing silicon nitride ceramics.

SINTX Technologies (NASDAQ: SINT) announced the acquisition of equipment and processes from B4C, LLC for manufacturing ballistic armor plates. Additionally, SINTX signed a technology license with Precision Ceramics USA Inc. to create a ceramic composite for defense applications. The new subsidiary, SINTX Armor, aims to produce high-strength Boron Carbide and a cost-effective Boron Carbide-Silicon Carbide composite. This move diversifies SINTX’s product offerings into military and law enforcement markets, addressing growing demand for advanced armor solutions.

SINTX Technologies (NASDAQ: SINT) announced a significant milestone by shipping its first batch of FleX SN-AP antipathogenic silicon nitride powder to O2TODAY for use in face masks and filters. This marks the next phase of their collaboration established during the COVID-19 pandemic. O2TODAY plans to begin limited pre-orders for these products on July 6, 2021. The agreement includes a two-year technology license, allowing exclusive use of SINTX's technology in these applications, promising potential royalties from product sales.

Oxford Performance Materials (OPM) and SINTX Technologies (NASDAQ: SINT) announced a collaboration to develop a new poly-ether-ketone-ketone (PEKK) silicon nitride composite using OPM’s patented casting technology.

This partnership aims to enhance medical implants' biological response and reduce infection rates, potentially leading to faster recovery and improved patient outcomes.

Both companies emphasize their shared focus on nanotechnology and surface technologies, suggesting that this collaboration could yield innovative products in the biomedical field.

SINTX Technologies, Inc. (NASDAQ: SINT) has been included in the Russell Microcap Index, effective June 4, 2021. This inclusion recognizes SINTX's financial progress and its focus on silicon nitride applications in biomedical and commercial markets. The Russell Microcap Index serves as a benchmark for institutional investors to evaluate micro-cap stocks with market caps between $50 and $300 million. CEO Dr. Sonny Bal emphasized that this achievement reflects SINTX's innovation in developing products like wound care, spinal and dental implants, and consumer facemasks.

SINTX Technologies announced the launch of its new FleX SN product line, expanding from monolithic spinal implants to various silicon nitride technologies. These products target biomedical and antipathogenic applications, including wound care and spinal implants, building on a proven safety record from over 40,000 surgeries. The rebranding also includes a redesigned website and the submission of a trademark application for FleX SN. The company aims to broaden its market focus in biomedical and industrial sectors.

SINTX Technologies announced multiple U.S. and international patent applications focusing on the development of technologies utilizing silicon nitride for antipathogenic applications. Key patents include methods for the rapid inactivation of SARS-CoV-2, antipathogenic face masks, and systems for applying silicon nitride coatings. These innovations aim to enhance medical devices and address viral diseases, including COVID-19. SINTX underscores its commitment to leveraging silicon nitride's properties in improving medical device outcomes. The company operates an FDA registered and certified manufacturing facility.

SINTX Technologies, Inc. (NASDAQ: SINT) filed its 10-K for the year ended December 31, 2020. Despite COVID-19's impact, SINTX adapted its strategic plan, highlighting that its silicon nitride effectively inactivates the SARS-CoV-2 virus. Key investments were made in personnel, collaborations, and capital equipment. SINTX is focused on developing antipathogenic products and is optimistic about its future as it approaches its 25th year in business. A conference call is scheduled for March 30, 2021, to provide further updates.

SINTX Technologies has announced that its silicon nitride-embedded fabrics effectively inactivate the SARS-CoV-2 virus. Testing conducted by the University of Rochester demonstrated a 99.9% reduction in viral loads upon contact. These antiviral fabrics have potential applications in face masks, surgical gowns, and air filters. Unlike traditional masks that use metal additives, SINTX's fabrics are non-allergenic and non-toxic. The company is focused on scaling production to meet the global demand for antiviral protective equipment.